Adjunctive Isradipine for the Treatment of Bipolar Depression

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by Massachusetts General Hospital
Sponsor:
Information provided by (Responsible Party):
Roy Perlis, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01784666
First received: February 4, 2013
Last updated: June 24, 2014
Last verified: June 2014

February 4, 2013
June 24, 2014
February 2013
February 2015   (final data collection date for primary outcome measure)
Change in MADRS (4 weeks) [ Time Frame: Baseline vs week 4 (and, for placebo nonresponders in 1st 4 weeks, week 8 vs week 4) ] [ Designated as safety issue: No ]
Change in Montgomery-Asberg Depression Rating Scale (MADRS) in isradipine-treated epochs versus placebo-treated epochs
Same as current
Complete list of historical versions of study NCT01784666 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Adjunctive Isradipine for the Treatment of Bipolar Depression
Adjunctive Isradipine for the Treatment of Bipolar Depression

This study investigates the medication isradipine, which is currently approved by the FDA to treat high blood pressure, in the treatment of depression in bipolar disorder. Isradipine or placebo (contains no active medication) will be used as an "add-on" to lithium, valproate, and/or atypical antipsychotics for individuals currently experiencing a major depressive episode. Our hypothesis is that isradipine will be superior to placebo in improving depressive symptoms.

Primary Aim: To estimate the antidepressant efficacy of isradipine versus placebo as an adjunct to lithium, valproate, and/or other atypical antipsychotics among individuals with bipolar I disorder in a nonpsychotic major depressive episode.

Hypothesis: Isradipine will be superior to placebo in improvement of depressive symptoms assessed by the Montgomery-Asberg Depression Rating Scale (MADRS).

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Treatment
Bipolar Disorder
  • Drug: Isradipine
    The study uses the Sequential Parallel Comparison design (SPCD), with two 4-week phases: n=30 subjects are randomized 1:1 to isradipine versus placebo add-on for 4 weeks, with the placebo nonresponders re-randomized 1:1 for a further 4 weeks. The SPCD will allow us to pool data from both phases to estimate the isradipine treatment effect. Subjects who respond in phase 1, and all subjects who receive isradipine in phase 1, continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed.
  • Drug: Placebo
    Subjects (n=15) are randomized to placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 to isradipine vs placebo for a further 4 weeks. Subjects who respond in phase 1 continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed.
  • Experimental: Isradipine-Isradipine
    Subjects will receive isradipine in phase 1 (4 weeks) and phase 2 (4 weeks)
    Intervention: Drug: Isradipine
  • Experimental: Placebo -> Isradipine
    Placebo non-responders after the 1st 4 weeks will be re-randomized 1:1 to placebo or isradipine for the next 4 weeks
    Interventions:
    • Drug: Isradipine
    • Drug: Placebo
  • Placebo Comparator: Placebo-Placebo
    Placebo nonresponders for the 1st 4 weeks will be re-randomized 1:1 to placebo or isradipine for the subsequent 4 weeks
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
30
August 2015
February 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age 18-65
  • written informed consent
  • meets DSM-IV criteria (by SCID-I/P) for bipolar I disorder, current episode depressed
  • MADRS score of at least 20 (i.e., moderate depression) and no greater than 34 (i.e., severe depression) at screen and baseline visit
  • YMRS score < 12 at screen and baseline visit
  • currently treated with a lithium preparation (carbonate or citrate) at stable dose for at least 4 wks with level >0.6 and <1.0; and/or valproate at stable dose for at least 4 wks at level >60 and <110; and/or other atypical antipsychotic at stable dose for at least 4 weeks (at least minimum FDA-labeled dose)
  • Caucasian by self-report - please see discussion below

Exclusion Criteria:

  • Psychotic features in the current episode, as assessed by YMRS item #8 > 6 [where treatment guidelines urge use of antipsychotics that may confound isradipine results]
  • felt by the study clinician to require inpatient hospitalization for adequate management (to include serious suicide or homicide risk, as assessed by evaluating clinician)
  • 3 or more failed pharmacologic interventions in the current major depressive episode, excluding lithium/valproate/other atypical antipsychotic [response rates for these subjects is likely to be extremely low and would require a substantially larger-scale study to identify treatment effects]
  • obsessive-compulsive disorder, or any diagnosis of a DSM-IV anxiety disorder where the anxiety disorder and not bipolar disorder is the primary focus of clinical attention
  • current substance use disorder other than nicotine, by SCID-I/P
  • a primary clinical diagnosis of a personality disorder, or comorbid diagnosis of antisocial or borderline personality disorder
  • pregnant women or women of child bearing potential who are not using a medically accepted means of contraception (to include oral contraceptive or implant, condom, diaphragm, spermicide, intrauterine device, tubal ligation, or partner with vasectomy)
  • women who are breastfeeding
  • other unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological disease, based on review of medical history, physical examination, and screening laboratory tests (this will include any clinical or laboratory evidence of hypothyroidism; if maintained on thyroid medication must be euthyroid for at least 1 month before Visit 1)
  • history of hypertension or current treatment for hypertension
  • current use of isradipine or history of anaphylactic reaction or intolerance to isradipine or any component of the preparation
  • ECG abnormalities at entry: prolonged QTc or complete or incomplete bundle branch block
  • patients who have taken an investigational psychotropic drug within the last 3 months
  • patients receiving other excluded antipsychotics or antidepressants within 2 weeks prior to study entry
  • patients requiring continued treatment with excluded medications (see below).

Excluded medications: antidepressants, antipsychotics, and anticonvulsants (other than valproate), which could influence calcium signaling or impact mood; other calcium channel blockers; any other antihypertensive because of the risk of cause hypotension; any other drug known to interact with isradipine. Benzodiazepines or other sedative-hypnotic agents (e.g., zolpidem) may not be initiated after study entry; subjects requiring these agents will be removed from the study. Allowed: Sedative-hypnotic agents if dosage has been stable for 4 weeks prior to study entry; thyroid or estrogen replacement provided dosage has been stable for 3 months. Acceptable anticonvulsants include lamotrigine, valproate, gabapentin, topiramate, oxcarbazepine, carbamazepine.

Both
18 Years to 65 Years
No
Contact: Roy H Perlis, MD, MSc rperlis@chgr.mgh.harvard.edu
Contact: Ashlee Roberson, BA aroberson2@mgh.harvard.edu
United States
 
NCT01784666
2012-P-002449/1
Yes
Roy Perlis, Massachusetts General Hospital
Massachusetts General Hospital
Not Provided
Principal Investigator: Roy H Perlis, MD, MSc Massachusetts General Hospital
Massachusetts General Hospital
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP